Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Canada / NCT07625202
Recruiting Not applicable

Creatine Supplementation During GLP-1a Therapy

NCT07625202 · tracked via the Priya Life Science Canada tracker
Sponsor
University of Saskatchewan
Phase
Not applicable
Started
2026-05-25
Last updated
2026-06-04

Condition(s) studied

Sarcopenia

Investigational drug(s) / intervention(s)

Dietary supplementation during a 12 week resistance-training program (creatine)Dietary supplementation during a 12 week resistance-training program (placebo)

Dietary supplementation during a 12 week resistance-training program (creatine): creatine supplementation

Dietary supplementation during a 12 week resistance-training program (placebo): Placebo

Study summary

GLP-1 receptor agonists are effective for weight loss, but significant muscle mass is lost as a proportion of this weight loss. This study combines resistance-training and creatine supplementation to try to prevent this loss of muscle mass.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * Starting GLP-1 agonist therapy * 18 years of age or older Exclusion Criteria: * Positive answers to a screening questionnaire for physical activity safety (the Get Active Questionnaire)

Primary outcome measure(s)

  • Change in sit to stand performance (number of times) — 12 weeks
    change in number of times sitting and standing in 30 seconds

Trial sites (1)

FacilityCityRegionStatus
University of Saskatchewan Saskatoon SK - Saskatchewan Recruiting

More University of Saskatchewan trials in Canada

Relative Bioavailability of Two Orally Administered CBD Formulations in Healthy Male Adults Recruiting
Impact of Milk and Yogurt Supplementation on Bone Health, Body Composition, and Gut Microbiota in Canadian Young Adults Recruiting
Effect of Intravenously Iron Infusion on the Prevention and Treatment of Anemia in Ovarian Cancer Starting soon
ECT with Ketamine Anesthesia Vs High Intensity Ketamine with ECT Rescue for Treatment-Resistant Depression Recruiting
Evaluation of 89Zr-DFO-nimotuzumab for Non-invasive Imaging of EGFR+ Cancers by Positron Emission Tomography (PET) Recruiting

Other trials for the same condition

Effects of Polyphenol Supplementation and Exercise on Physical Performance in Older Adults Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07625202 on ClinicalTrials.gov ↗ ← All trials in Canada